---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-250638"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:08:31.443351+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Verrica Q3 net product revenue negative $1.9M; CEO Ted White resigns, replaced by Dr. Rieger

## Summary
- Negative net product revenue of $1.9M in Q3 2024, including $1.7M provision for returns; no ex-factory sales.
- Net loss of $22.9M ($0.49 per share) vs $24.8M ($0.54) in Q3 2023; non-GAAP loss $20.2M.
- CEO Ted White resigns effective Nov 5; Dr. Jayson Rieger appointed President, CEO, and director.
- John Kirby appointed Interim CFO; company engaged Jefferies to advise on strengthening balance sheet.
- Restructuring cuts operating expenses ~50%; VP-315 Phase 2 shows 51% complete histologic clearance for BCC.

## SEC filing metadata
- accession: 0001193125-24-250638
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312524250638/0001193125-24-250638-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312524250638/d907851d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-250638
- JSON: https://secwatch.observer/filing/0001193125-24-250638.json
- Plain text: https://secwatch.observer/filing/0001193125-24-250638.txt

## Key facts
- Executive change
  Jayson Rieger was appointed as President and Chief Executive Officer at Verrica Pharmaceuticals Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On November 1, 2024, the Board appointed Dr. Jayson Rieger as the Company’s President, Chief Executive Officer, and as member of the Board and designated him as the Company’s principal executive officer, each effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312524250638/0001193125-24-250638-index.htm
- Executive change
  Ted White resigned as President and Chief Executive Officer at Verrica Pharmaceuticals Inc..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: On November 1, 2024, Ted White notified the Company that he will resign from his positions as the Company’s President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “ Board ”) effective as of November 5, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312524250638/0001193125-24-250638-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.